Epoetin alfa and outcomes in dialysis amid regulatory and payment reform

Journal of the American Society of Nephrology

Volumn 27, Issue 10, 2016, Pages 3129-3138

  Chertow, Glenn M ^a   Liu, Jiannong ^b   Monda, Keri L ^c   Gilbertson, David T ^b   Brookhart, M Alan ^d   Beaubrun, Anne C ^c   Winkelmayer, Wolfgang C ^a,e   Pollock, Allan ^f   Herzog, Charles A ^b,g   Ashfaq, Akhtar ^f   Sturmer, Til ^d   Rothman, Kenneth J ^h   Bradbury, Brian D ^c   Collins, Allan J ^a,g  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^c Center for Observational Research   (United States)

^d IL   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f AMGEN INC   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^h RTI HEALTH SOLUTIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT;

ADULT; ALL CAUSE MORTALITY; ANEMIA; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; COMORBIDITY; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HEALTH CARE POLICY; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HOSPITAL READMISSION; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MEDICARE; MIDDLE AGED; MORTALITY RATE; OPEN STUDY; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RISK FACTOR; UNITED STATES; VENOUS THROMBOEMBOLISM; VIRUS VIRULENCE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; MORTALITY; PRESCRIPTION; REIMBURSEMENT; STANDARDS;

CARDIOVASCULAR DISEASES; COHORT STUDIES; DRUG PRESCRIPTIONS; EPOETIN ALFA; FEMALE; HEMATINICS; HUMANS; MALE; MEDICARE; MIDDLE AGED; PRACTICE PATTERNS, PHYSICIANS'; REIMBURSEMENT MECHANISMS; RENAL DIALYSIS; UNITED STATES;

EID: 85011272837     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2015111232     Document Type: Article

References (31)

1. Churchill DN, Taylor DW, Cook RJ, LaPlante P, Barre P, Cartier P, Fay WP, Goldstein MB, Jindal K, Mandin H, McKenzie JK, Muirhead N, Parfrey PS, Posen GA, Slaughter D, Ulan RA, Werb R: Canadian Hemodialysis Morbidity Study. Am J Kidney Dis 19: 214-234, 1992
2. US Renal Data System: USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2010
3. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with lowhematocrit values in patientswith cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998
4. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006
5. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF,McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009
6. Amgen Inc.: Prescribing information for Epogen (epoetin alfa). Approved May 2012. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/103234s5281lbl.pdf. Accessed September 22, 2015
7. Amgen Inc.: Prescribing information for Aranesp (darbepoetin alfa). Revised March 2015. Available at http://pi.amgen.com/united-states/aranesp/ckd/aranesp-pi-hcp-english.pdf.Accessed September 22, 2015
8. Joynt KE, Jha AK: A path forward on Medicare readmissions. N Engl J Med 368: 1175-1177, 2013
9. Medicare Program; Proposed Changes to the Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed Fiscal Year 2011 Rates; Effective Date of Provider Agreements and Supplier Approvals; and Hospital Conditions of Participation for Rehabilitation and Respiratory Care Services Medicaid Program: Accreditation Requirements for Providers of Inpatient Psychiatric Services for Individuals Under Age 21. Federal Register. 2010. Available at https://www.federalregister.gov/articles/2010/05/04/2010-9163/medicare-programproposed-changes-to-The-hospital-inpatient-prospective-paymentsystems-for-acute. Accessed September 22, 2015
10. Medicare Program; Hospital Inpatient Value-Based Purchasing Program. Federal Register. 2011. Available at https://www.federalregister.gov/articles/2011/05/06/2011-10568/medicare-program-hospital-inpatientvalue-based-purchasing-program. Accessed September 22, 2015
11. Brunelli SM, Gagne JJ, Huybrechts KF, Wang SV, Patrick AR, Rothman KJ, Seeger JD: Estimation using all available covariate information versus a fixed look-back window for dichotomous covariates. Pharmacoepidemiol Drug Saf 22: 542-550, 2013
12. Gilbertson DT, Bradbury BD, Wetmore JB,Weinhandl ED, Monda KL, Liu J, BrookhartMA, Gustafson SK, Roberts T, CollinsAJ, RothmanKJ:Controlling confounding of treatment effects in administrative data in the presence of time-varying baseline confounders [published online ahead of print November 26, 2015]. Pharmacoepidemiol Drug Saf doi: 10.1002/pds.3922
13. Tirschwell DL, Longstreth WT Jr: Validating administrative data in stroke research. Stroke 33: 2465-2470, 2002
14. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH: Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: Estimating positive predictive value on the basis of review of hospital records. Am Heart J 148: 99-104, 2004
15. Saran R, Li Y, Robinson B: USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2014
16. Bradbury BD, Wang O, Critchlow CW, Rothman KJ, Heagerty P, Keen M, Acquavella JF: Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis 51: 62-70, 2008
17. Bradbury BD, DaneseMD, GleesonM, Critchlow CW: Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below11 g/dL. Clin J AmSoc Nephrol 4: 630-637, 2009
18. Zhang Y, ThamerM, Cotter D, Kaufman J, HernánMA: Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Clin J Am Soc Nephrol 4: 638-644, 2009
19. Bradbury BD, Do TP, Winkelmayer WC, Critchlow CW, Brookhart MA: Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. Pharmacoepidemiol Drug Saf 18: 932-940, 2009
20. Wang O, Kilpatrick RD, Critchlow CW, Ling X, Bradbury BD, Gilbertson DT, Collins AJ, Rothman KJ, Acquavella JF: Relationship between epoetin alfa dose and mortality: findings from a marginal structural model. Clin J Am Soc Nephrol 5: 182-188, 2010
21. Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Liu J, Winkelmayer WC: Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 303: 857-864, 2010
22. Weinhandl ED, Gilbertson DT, Collins AJ: Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients. Am J Nephrol 34: 298-308, 2011
23. Dialysis Outcomes and Practice Patterns Study Program: DOPPS Practice Monitor. August 2015. Available at http://www.dopps.org/DPM. Accessed September 22, 2015
24. Brunelli SM, Monda KL, Burkart JM, Gitlin M, Neumann PJ, Park GS, Symonian-Silver M, Yue S, Bradbury BD, Rubin RJ: Early trends fromthe Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS). Am J Kidney Dis 61: 947-956, 2013
25. Brookhart MA, Freburger JK, Ellis AR,Wang L, Winkelmayer WC, Kshirsagar AV: Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 24: 1151-1158, 2013
26. US Renal Data System: USRDS 2015 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2015
27. Bradbury BD, Fissell RB, Albert JM, Anthony MS, Critchlow CW, Pisoni RL, Port FK, Gillespie BW: Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 2: 89-99, 2007
28. Robinson BM, Tong L, Zhang J, Wolfe RA, Goodkin DA, Greenwood RN, Kerr PG,Morgenstern H, Li Y, Pisoni RL, Saran R, Tentori F, Akizawa T, Fukuhara S, Port FK: Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 82: 570-580, 2012
29. Soucie JM, McClellan WM: Early death in dialysis patients: Risk factors and impact on incidence and mortality rates. J Am Soc Nephrol 7: 2169-2175, 1996
30. Collins AJ, Foley RN, Gilbertson DT, Chen SC: The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol 4[Suppl 1]: S5-S11, 2009
31. Foley RN, Collins AJ: End-stage renal disease in the United States: An update from the United States Renal Data System. J Am Soc Nephrol 18: 2644-2648, 2007